

July 17, 2024

National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001

Symbol: **ORCHPHARMA** 

Scrip Code: **524372** 

Subject: Outcome of the Board Meeting - Orchid Pharma Limited ("the Company") held on July 17, 2024

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Para A of Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, we would like to inform you that the Board of Directors of the Company at their meeting held today *i.e.* July 17, 2024 [commenced at 01.00 P.M. (IST) and concluded at 07.45 P.M. (IST)] has *inter-alia* considered and approved the below mentioned matters:

- **1.** The cut-off date for determining the shareholders eligible for receive the notice of Annual General Meeting, shall be Friday, July 19, 2024 and for e-voting i.e. shareholders eligible to vote on the resolutions in notice of Annual General Meeting, shall be Monday, August 12, 2024. The Remote e-voting period will commence on August 17, 2024 (9:00 A.M. IST) and ends on August 20, 2024 (5:00 P.M. IST).
- **2.** Appointed M/s. National Securities Depositories Limited ("NSDL") as the agency to provide the e-voting facility to the shareholders of the Company and Mr. Muthukumaran (Membership No. F11218 & Certificate of Practice No. 20333), Partner, M/s. P Muthukumaran & Associates, Practicing Company Secretaries, as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.
- **3.** Mr. Ram Gopal Agarwal (DIN: 00627386) to continue the office of Non-Executive Director under Regulation 17(1A) of SEBI Listing Regulations, who will be attaining the age of 75 years subject to the approval of the Shareholders, via Special Resolution at the ensuing Annual General Meeting.
- **4.** Re-Appointment of Mr. Manish Dhanuka (DIN:00238798) as Managing Director of the company for another term of 5 consecutive years, commencing from February 28, 2025 to February 27, 2030 ("Period") and Remuneration payable to him during the period, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting.
- **5.** Re-Appointment of Mr. Mridul Dhanuka (DIN: 00199441) as Whole Time Director of the company for another term of 5 consecutive years, commencing from February 28, 2025 to February 27, 2030("Period") and Remuneration payable to him during the period, subject to the approval of the Shareholders of the Company at the ensuing Annual General Meeting.

Further, the details required for Point no. 3, 4 & 5 in terms of Schedule III – Sub-Para 7 of Para A of Part A of the Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 issued in this regard, are given in the annexure enclosed herewith as **Annexure-I.** 



You are requested to take the above intimation on record.

Thanking You, For **Orchid Pharma Limited** 

Kapil Dayya Company Secretary & Compliance Officer M. No.: F10698

Encl.: as above



#### **Annexure-I**

Information as required under Regulation 30 - Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Particulars	Information w.r.t Mr. Ram Gopal Agarwal	Information w.r.t Mr. Manish Dhanuka	Information w.r.t Mr. Mridul Dhanuka
1	Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Continuation of Directorship under Regulation 17(1A) of SEBI Listing Regulations	Re-appointment	Re-appointment
2	Date of appointment/cessation (as applicable) & term of appointment	To continue office w.e.f. July 30, 2024 as Non-Executive Director without any defined term and subject to retire by rotation.	Appointed for a term of 5 years w.e.f. February 28, 2025.	Appointed for a term of 5 years w.e.f. February 28, 2025.
3	Brief profile (in case of appointment)	Please refer Annexure-II	Please refer Annexure-III	Please refer Annexure-IV
4	Disclosure of relationships between directors (in case of appointment of a director)			



### **Annexure-II**

## Brief Profile of Mr. Ram Gopal Agarwal, Non- Executive Director

Particulars				
Name of Director	Mr. Ram Gopal Agarwal			
DIN	DIN: 00627386			
Date of Birth	July 30, 1949			
Age	74 years			
Qualification	Bachelor of Commerce (Honours)			
Brief Profile/ Experience/ Skills/ Expertise	Shri Ram Gopal Agarwal is Founder Chairman of Dhanuka Group. He has 56 years of rich and wide experience in the Industry. He is a decisive and action oriented visionary who took over a sick pesticide Company named Northern Mineral Pvt. Ltd. in 1980 and transformed it today into a Rs 1000 Crore organization. His deep commitment and inspiring leadership in initial turbulent days is an example worth inculcating. He was the past Chairman of CCFI, (Crop Care Federation of India) the apex Chamber of all Indian Agrochemical majors. He has as been bestowed with many Awards for his tremendous contribution in Agro Industry like "Life Time Achievement Award" by Agri Business Summit and Agri Awards 2019, "Distinguished Contribution to Indian Agrochemicals Industry" during India Chem 2016 International Conference organised by FICCI etc.			
Inter-se relationships with Directors and Key Managerial Personnel	Mr. Ram Gopal Agarwal is cousin brother of Mr. Manish Dhanuka, Managing Director and Uncle of Mr Mridul Dhanuka, Whole Time Director and Mr. Arjun Dhanuka, Non-Executive Director.			



### **Annexure- III**

## Brief Profile of Mr. Manish Dhanuka, Managing Director

Particulars				
Name of the Director	Mr. Manish Dhanuka			
DIN	00238798			
Date of Birth	28.09.1967			
Age	56 Years			
Qualification	Mr. Manish Dhanuka holds a B. Tech in Chemical Engineering from IIT, New Delhi, and M.S in Chemical Engineering from the University of Akron, USA			
Brief Profile/ Experience/ Skills/ Expertise	Mr. Manish Dhanuka has 25 years of rich experience in research, evaluation, and teaching in the pharmaceutical industry with the expertise in innovative pharmaceutical technologies. He excels in creating economical pharmaceutical technologies and accelerated evaluation process for improving healthcare. His wide-ranging experience of handling operations, commercial, marketing and Finance in the manufacturing industry provides for his analytical and decision-making skills facilitating the restoration of the company to its glorious past and to achieve even greater heights. Before establishing Dhanuka laboratories Ltd. In 1993, he began his career at Ranbaxy Labs Ltd. in New Delhi and worked there for 5 years. His vision and strategy to grow the Pharmaceutical industry in the Indian sub- continent, have helped the Dhanuka Group of companies enhance its Bulk Drugs manufacturing arm exponentially. He spearheaded the acquisition of Synmedic Laboratories in the year 2013 which is involved in pharmaceutical formulations. This entrepreneurial vigor enabled him to take over the operations of Orchid Pharma Ltd.in March 2020. Mr. Manish Dhanuka has the vision to rejuvenate Orchid Pharma Ltd. and take it on a fruitful path.			
Inter-se relationships with Directors and Key Managerial Personnel	, , ,			



### **Annexure- IV**

# Brief Profile of Mr. Mridul Dhanuka, Whole-time Director

Particulars				
Name of Director	Mr. Mridul Dhanuka			
DIN	00199441			
Date of Birth	20.10.1980			
Qualification	Mr. Mridul Dhanuka is a Chemical Engineer with a Master's Degree in Business Administration.			
Brief Profile/ Experience/ Skills/ Expertise	Mr. Mridul Dhanuka has wide experience of 16 years. He is associated with Dhanuka Group Ltd. since 2005. His technical expertise has supported to enlarge the product base of Dhanuka. He helped the Company in smoothening the production, procurement and logistic functions and established quality control.  As Director Operations he is instrumental in driving various initiatives with the support of senior leadership teams to achieve the set milestones of the organization. Under his exuberant personality and ambitious leadership the Company was able to expand its production facilities, setting up a state of art world class manufacturing facility at Keshwana, Rajasthan. He was responsible in successfully realigning the entire supply chain vertical from procurement to sales.  He has successfully improved the efficiency and productivity of all the manufacturing facilities of Dhanuka thereby making a positive contribution in the profitability of the Company.			
Inter-se relationships with Directors and Key Managerial Personnel	Executive Director and Mr. Manish Dhanuka, Managing Director and cousin			